Fangzhou Inc. showcased its innovations at the 'AI Empowers Biopharma' panel on April 3, 2025, in Guangzhou, China, where it participated alongside 28 other enterprises to discuss advancements in AI healthcare.

During the panel, Guo Zhi, Senior Vice President of Technology at Fangzhou, presented the company's AI + H2H Smart Healthcare Ecosystem, designed to enhance healthcare delivery by providing services directly to patients' homes.

This ecosystem encompasses chronic disease management, patient education, and medication delivery, significantly improving accessibility and timeliness in care.

Fangzhou is recognized as China's leading online chronic disease management platform, boasting 49.2 million registered users and 223,000 physicians as of the end of 2024.

To support its healthcare initiatives, Fangzhou introduced the 'AI Agent Matrix,' which offers 24/7 diagnostic assistance and intelligent customer service tools, aimed at reducing operational costs and improving care access.

The company also implemented a proprietary framework to mitigate AI hallucinations in medical applications, integrating a training platform with a medical knowledge base to enhance the accuracy of its AI technologies.

Fangzhou's growth strategy focuses on deploying advanced AI technologies like DeepSeek-V3 and forming partnerships with industry leaders such as Tencent Health and Tencent Cloud to accelerate the adoption of AI healthcare solutions.

The company aims to deepen its focus on AI in healthcare, seeking collaborations with biopharmaceutical companies and research institutions to enhance the integration of AI in healthcare applications.

The 'AI Empowers Biopharma' panel is part of the Guangzhou Development District's initiative to establish itself as a leader in biopharmaceutical innovation, emphasizing AI-driven research and smart healthcare ecosystems.